Insulin Therapy: Practical Clinical Aspects
While oral medications are the most common initial treatment of type 2 diabetes, oral monotherapy usually fails to control glucose levels over time. Findings have shown that after 3 years of monotherapy for type 2 diabetes, 50% of patients require combination therapy. After 9 years of monotherapy, that proportion rises to 75%. Nevertheless, even combination therapy eventually fails to control blood glucose levels in most patients. At this point, insulin therapy becomes necessary.
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
